What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GHRH 1-29 fragment
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Sermorelin inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Sermorelin is the unmodified 29-amino-acid N-terminal fragment of native human GHRH (residues 1-29), retaining the full receptor-binding activity of the parent 44-residue molecule. Approved historically as a prescription drug (Geref) for pediatric GH deficiency diagnosis, Sermorelin is the most studied GHRH-receptor agonist and serves as the reference compound against which engineered analogues (CJC-1295, Tesamorelin, Modified GRF 1-29) are compared. The molecule's clinical pharmacokinetic limitation, a serum half-life of roughly 10-12 minutes due to DPP-4 cleavage at the Tyr1-Ala2 bond, is the design problem that motivated the substitution chemistry behind the CJC-1295 family. PeptideXpo supplies Sermorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The 29-residue sequence is within reliable SPPS range and the analytical packet covers peak-integration HPLC, ESI mass spec, water content, and counter-ion. Sermorelin is typically used in research contexts studying GHRH-receptor pharmacology at physiologically relevant time scales (the short half-life is a feature, not a bug, for pulse-pharmacology research) and in compounding workflows where the short-acting profile is appropriate. For sustained-action profiles, buyers generally route to CJC-1295 with DAC instead.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
All three are GHRH-receptor agonists, but they differ in their pharmacokinetic engineering. Sermorelin is the unmodified GHRH(1-29) fragment with a roughly 10-minute serum half-life, the native molecule's properties. CJC-1295 (no DAC) adds four amino-acid substitutions that resist DPP-4 cleavage, extending half-life to roughly 30 minutes while retaining the physiological pulsatile signaling pattern. Tesamorelin adds an N-terminal trans-3-hexenoyl group, similarly improving protease resistance and extending half-life, Tesamorelin is the only FDA-approved member of this family, indicated for HIV-associated lipodystrophy. CJC-1295 with DAC sits at the far end of the half-life spectrum at roughly a week via albumin binding.
Research workflows studying GHRH-receptor pharmacology often need to characterize pulsatile signaling at physiologically relevant timescales, sustained-elevation models produce different downstream biology than pulse-pattern models because GH-release feedback loops respond to pulse architecture, not just average exposure. Sermorelin's short half-life makes it the cleanest tool for studying pulse-pharmacology, dose-response within a single GH pulse, and acute receptor pharmacology. For sustained-elevation research or for clinical contexts where convenience matters, the longer-acting CJC-1295 (no DAC) or CJC-1295 with DAC are preferred.
Yes, the GHRH-pathway plus GHSR-pathway combination strategy applies to Sermorelin the same way it applies to CJC-1295: combining a GHRH-receptor agonist with a GHSR agonist produces additive GH-release magnitudes beyond either component alone. The Sermorelin + Ipamorelin combination is less common than CJC-1295 + Ipamorelin in published research and compounding workflows simply because CJC-1295's longer half-life better matches Ipamorelin's, but for short-pulse research applications the Sermorelin combination is mechanistically equivalent.
Related peptides
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
44-mer
GHRH analog · approved for HIV-associated lipodystrophy
